

YOUR INVITATION TO ATTEND:

GeneSight® in Clinical Practice

A MYRIAD GENETICS SPEAKER PRESENTATION

A clinical and scientific discussion focusing on the basics of pharmacogenomics and review of the GeneSight® Psychotropic report and clinical data. Q&A to follow.



PRESENTER

Morgan Freas, PharmD

Senior Medical Science Liaison

Dr. Morgan Freas is an Executive Medical Science Liaison (MSL) at Myriad Genetics, based in the Dallas-Fort Worth Metroplex, where she is a subject expert on pharmacogenomic testing in mental health. She completed her Bachelor of Science in Biology at Mercer University in Macon, GA before going on to the University of North Texas Health Science Center in Fort Worth to receive her Doctorate of Pharmacy degree (PharmD). She has received a certificate in pharmacogenomics from the American Society of Health-System Pharmacists (ASHP) and as a licensed pharmacist and MSL at Myriad, Dr. Freas has given countless presentations on scientific topics related to pharmacogenomics, mental health, and health equity and has a robust interest in advancing pharmacist involvement in pharmacogenomic testing through medication management.

DATE & TIME

Thursday, April 10, 2025
6:00pm

LOCATION

Shapley's Restaurant
868 Centre St
Ridgeland, MS 39157

QUESTIONS

George Johnson
Sales Executive
george.johnson@myriad.com
(225) 936-5335

RSVP

Please RSVP by
April 9, 2025

This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend.

The GeneSight® Psychotropic test is a genetics-based decision support tool that analyzes clinically important genetic variations that may affect your patient's outcomes with certain psychiatric medications. Use of the GeneSight Psychotropic test can help inform your medication selection. The results show which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on your patient's genetic makeup. The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in seven published, peer-reviewed clinical trials. In the GUIDED study, patients in the GeneSight arm experienced an 11% relative improvement in symptoms, a 30% relative improvement in response rates, and a 50% relative improvement in remission rates compared to treatment as usual at week 8.



6960 Cintas Blvd
Mason, OH 45040
866.260.2394



www.genesight.com